Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan

Murakawa, Yasuko; Sakayori, Masato; Otsuka, Kazunori

doi:10.1186/s12904-019-0428-3

Cited by 14 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DFI less than 12 months often symbolizes short-term recurrence, which we speculate may be related to poor treatment [ 22 , 23 ]. In the study of Murakawa et al [ 24 ], the treatment mode is obviously related to OS of tumor patients, which is different from our research results. As for the relationship between PC and poor prognosis of REC patients, we speculate that this may be related to the nonlocality of the lesion range.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Yang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Recurrence of endometrial cancer after initial treatment can be complex and difficult to treat. The current main treatment modalities for patients with recurrent endometrial cancer (REC) include chemotherapy, radiotherapy, and surgery, which vary according to the individual patient. However, REC is often associated with a poor prognosis, and it is therefore important to investigate the risk factors affecting REC prognosis and to explore appropriate treatment modalities to improve the prognosis and treatment strategies for patients with REC. Methods. Totally, 100 patients with REC admitted to our hospital from January 2013 to January 2018 were chosen to be research objects. Their pathological data were analyzed, including age, disease-free interval (DFI), recurrence site, and treatment plan after relapse (definitive local therapy (DLT) and palliative chemotherapy (PC)). According to these parameters, univariate and multivariate factors affecting the prognosis of REC patients and the curative effect of PC were analyzed, and the 3-year overall survival (OS) curve and progression-free survival (PFS) curve were drawn. Results. After 3 years of follow-up, 30 patients had a poor prognosis and 70 had a good prognosis, according to which a single multifactorial analysis was performed for different prognoses, where the results of the single-factor analysis showed significant differences between patients with different prognoses in terms of pathomorphology, pathological grading, TFI, and treatment modality after relapse. Further multifactorial analysis showed that TFI and treatment modality after recurrence were independent factors affecting poor prognosis in REC patients. The 3-year OS and 3-year PFS of REC patients were 74.00% and 70.00%, respectively. Patients whose DFI was less than 12 months or treated with PC after relapse were notably associated with lower levels of 3-year OS and 3-year PFS. In addition, radiotherapy and chemotherapy, DFI, and chemotherapy plan after primary surgery were independent risk factors that affected the PC efficacy of REC patients. Conclusion. DFI and treatment mode after relapse are independent factors affecting the prognosis of REC patients. DLT can obviously improve the prognosis of REC patients. For patients who can only choose PC, chemoradiotherapy and DFI after primary surgery are helpful to predict the chemotherapy effect, and the combination of paclitaxel and platinum drugs should be the first choice for chemotherapy.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 95%

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Yang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…This was not possible to ascertain since no data on performance status existed on the non-PCS patients. We observed that non-PCS patients were less likely to be receiving chemotherapy at referral, and some investigators have shown that patients with poor performance status are less likely to consent to palliative chemotherapy 26 . Thus, one could infer that the reduced use of chemotherapy in the non-PCS group is indicative of worse performance status.…”

Section: Discussionmentioning

confidence: 58%

Palliative care reduces emergency room visits and total hospital days among patients with metastatic HPB and GI cancers

Billiot

Danos

Stevens

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Palliative care services (PCS) have improved quality of life for patients across various cancer subtypes. Minimal data exists regarding PCSfor metastatic hepatopancreaticobiliary (HPB) and gastrointestinal (GI) cancers. We assessed the impact of PCS on emergency department visits, hospital admissions, and survival among these patients. Patients with metastatic HPB and GI cancer referred to outpatient PCS between 2014 and 2018 at a single institution were included. We compared the demographics, outcomes, and end-of-life indicators between those who did and did not receive PCS. The study included 183 patients, with 118 (64.5%) having received PCS. There were no significant differences in age, gender, race, marital status, or insurance. Those receiving PCS were more likely to have colorectal cancer (p = 0.0082) and receive chemotherapy (p = 0.0098). On multivariate analysis, PCS was associated with fewer ED visits (p = 0.0319), hospital admissions (p = 0.0002), and total inpatient hospital days (p < 0.0001) per 30 days of life. Overall survival was greater among patients receiving PCS (HR: 0.65 (0.46–0.92)). Outpatient PCS for patients with metastatic HPB and GI cancer is associated with fewer emergency department visits, hospital admissions, and inpatient hospital days, and improved overall survival.

show abstract

“…The American Society of Clinical Oncology advocates withholding palliative chemotherapy from patients with solid tumors and an ECOG PS of 3-4, and instead recommends best supportive care (BSC) [4]. However, in our previous study [5], almost half of patients with an ECOG PS of 3-4 selected palliative chemotherapy, while patients with an ECOG PS of 0-2 did not experience prolonged survival with palliative chemotherapy when compared to patients with an ECOG PS of 3-4.…”

Section: Trajectories Of Hospitalization In Three Groups Of Patients mentioning

confidence: 82%

Trajectories of hospitalization in three groups of patients with incurable gastric cancer identified by hierarchical clustering: A retrospecitve analysis

Murakawa

Sakayori

Otsuka

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: The therapeutic goal for advanced solid malignancies is not to achieve cure but to prolong survival and maintain quality of life (QOL). To date, no study has reported the trajectory of the QOL throughout the clinical course of a patient with advanced malignancy. As hospitalization is considered a predictor of QOL, we retrospectively analyzed the trajectory of hospitalization in patients with incurable gastric cancer throughout the clinical course. Methods: The data of 85 patients with incurable gastric cancer were collected, including age, sex, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), treatment, histology, sites of metastases at first consultation, planned and unplanned hospitalization throughout the clinical course , and overall survival (OS). We ranked the patients by OS and hospitalization using a hierarchical clustering analysis. Results: Three clusters were identified corresponding to short, intermediate, and long OS/hospitalization (Clusters 1, 2, and 3, respectively). Patients in Cluster 3 were more likely to have an ECOG PS of 0–2 and receive palliative chemotherapy than the other clusters. No other differences in histology, age, sex, and or extra-peritoneal metastasis sites were observed between the three groups. In Cluster 3, planned hospitalization accumulated gradually during the early clinical phase, while unplanned hospitalization accumulated rapidly in later phases. Conclusions: No specific characteristics were associated with short, intermediate, and long OS/hospitalization. Patients in the long OS/hospitalization group exhibited a rapid accumulation of unplanned hospitalization during the latter clinical course. Further research is needed to identify specific predictors of and measures to avoid a long OS/hospitalization.

show abstract

Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan

Cited by 14 publications

References 40 publications

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Palliative care reduces emergency room visits and total hospital days among patients with metastatic HPB and GI cancers

Trajectories of hospitalization in three groups of patients with incurable gastric cancer identified by hierarchical clustering: A retrospecitve analysis

Contact Info

Product

Resources

About